Novartis IndiaBOM:500672 +0.17%59 EBITDA Margin % is 33.83% as of Mar. 2026, which is 30% above its 10-year median of 26.06. GuruFocus rates BOM:500672 with a GF Score™ of 59/100 and a GF Value™ of ₹928.24 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 952 Drug Manufacturers companies, Novartis India ranks better than 92.23% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Novartis India's EBITDA for the
three
months ended in Mar. 2026 was ₹306 Mil. Novartis India's Revenue for the
three
months ended in Mar. 2026 was ₹906 Mil. Therefore, Novartis India's EBITDA margin for the quarter that ended in Mar. 2026 was 33.83%.
Novartis India (BOM:500672) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Novartis India EBITDA Margin % Related Terms
Novartis India EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Novartis India's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:500672 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Novartis India's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novartis India EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Novartis India's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Novartis India's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novartis India (BOM:500672) has a EBITDA Margin % of 33.83% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Novartis India and its competitors. This is 30% above median its historical median of 26.06. Over the past decade, Novartis India's EBITDA Margin % has ranged from 2.75 to 38.00. According to the industry distribution chart, Novartis India ranks #74 out of 952 companies in the Drug Manufacturers industry, placing it in the top 7.8%.
Is Novartis India's EBITDA Margin % too high?
Novartis India's current EBITDA Margin % of 33.83% is 30% above median its 10-year median of 26.06. Over the past 10 years, this metric has ranged from a low of 2.75 to a high of 38.00. The Drug Manufacturers industry median EBITDA Margin % is 12.47. Novartis India's value of 33.83% is 171.3% above this industry median. Based on the distribution chart, Novartis India ranks #74 out of 952 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Novartis India has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novartis India's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Novartis India ranks #74 out of 952 companies for EBITDA Margin %. This places Novartis India in the top 8% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.47. Novartis India's value of 33.83% is 171.3% above this benchmark. Historically, Novartis India's own EBITDA Margin % has ranged from 2.75 to 38.00 over the past decade. While the company's 10-year median is 26.06 vs. the industry median of 12.47, Novartis India has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.47, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novartis India's current EBITDA Margin % of 33.83% is 171.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Novartis India and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novartis India's current EBITDA Margin % is 33.83%, which is 30% above median its own 10-year median of 26.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novartis India stock overvalued right now?
Based on GuruFocus' analysis, Novartis India (BOM:500672) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹928.24, compared to a current price of ₹1,440.95 — trading 55.2% above its estimated fair value. The current EBITDA Margin % is 33.83%, which is 30% above median its 10-year median of 26.06 and 171.3% above the Drug Manufacturers industry median of 12.47. Novartis India's overall GF Score™ is 59/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Novartis India (BOM:500672), the current EBITDA Margin % is 33.83% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novartis India (BOM:500672) Overvalued in 2026?
Based on GuruFocus' analysis, Novartis India stock appears to be overvalued.
The current stock price of ₹1,440.95 is trading 55.2% above its estimated GF Value™ of ₹928.24.
GuruFocus considers Novartis India to be Significantly Overvalued.
Key valuation signals for BOM:500672:
EBITDA Margin %: 33.83% (30% above median its 10-year median of 26.06)
GF Value™: ₹928.24 vs. price of ₹1,440.95 (55.2% above fair value)
Industry Position: 171.3% above the Drug Manufacturers median (#74 of 952)
No single metric tells the full story. See the BOM:500672 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novartis India Ltd is an Indian-based pharmaceutical company. The company is engaged in the trading of Drugs and Pharmaceuticals. It derives revenue from operations in India. The company operates in a single business segment, namely Pharmaceutical Business. Its Pharmaceutical business focuses on Bone and Pain, Transplantation Immunology, and Neurosciences.
59GF Score
Get the complete analysis for BOM:500672
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:500672 has been successfully added to your 
